eISSN: 2354-0265
ISSN: 2353-6942
Health Problems of Civilization Physical activity: diseases and issues recognized by the WHO
Current issue Archive Online first About the journal Editorial board Reviewers Abstracting and indexing Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
4/2017
vol. 11
 
Share:
Send email
Share:
OTHER
abstract:
Original paper

EFFICIENCY OF BIOFLAVONOID QUERCETIN AND RNA-CONTAINING DRUG SODIUM NUCLEINAT IN COMPLEX TREATMENT OF PATIENTS WITH MYOCARDIAL INFARCTION AND FUNCTIONAL LIVER DISORDERS

Mykola Shved
1
,
Olena Prokopovych
1
,
Sofiya Lypovetska
1
,
Svitlana Heryak
1
,
Yaroslav Kitsak
1

  1. I. Horbachevsky Ternopil State Medical University; Ministry of Public Health, Ukraine
Health Prob Civil. 2017; 11(4): 293-299
DOI: https://doi.org/10.5114/hpc.2017.71891
Online publish date: 2018/01/24
View full text Get citation
 
PlumX metrics:
Background. The study has shown that functional liver disorders develop in patients with MI, which requires correction.

Material and methods. The study involved 149 patients with acute MI. All examinations were repeated several times on the 1, 14 and 28 day of the treatment.

Results. The patients with functional liver disorders have a higher incidence of epistenocardial pericarditis, arrhythmia and systolic dysfunction. They are characterised by highly activated lipid peroxidation and immunological disorders. A combined therapy with quercetin resulted in improving hemodynamics and reducing the manifestations of liver dysfunction. RNA-containing drug significantly improved the immune status and reduced signs of immuno-inflammatory syndromes.

Conclusions. 1.In patients with MI and functional liver disorders, the primary pathological process is characterised by significant violations of systolic and diastolic function of the heart, more frequent development of complications, activation of lipid peroxidation and secondary immunodeficiency. 2. The inclusion of bioflavonoid quercetin in the treatment of patients with MI helps to restore the antioxidant defence system, improve myocardial contractile function and reduce clinical laboratory manifestations of cytolytic and cholestatic syndromes in patients due to antioxidant and membrane stabilizing properties of the drug. 3. The usage of the RNA-containing drug Nuclex improves immune reactivity, reduces symptoms of expressed mesenchymal-inflammatory and necro-resorptive syndromes in patients with MI and functional liver disorders.
keywords:

myocardial infarction, liver function, lipid peroxidation, quercetin, sodium nucleinat

Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.